1Stefania M, Marianna N, Pietro G, et al. Metabolic Syndrome, Diabetes, and Cardiovascular Disease in an Elderly Caucasian Cohort:The Italian Longitudinal Study on Aging [ J ]. The Journals of Gerontology,2006,61 (5) :505 -560.
2Atul G, Agarwal P. metabolic syndrome[ J ]. Indian Journal of Medical Sciences ,2006,60(2) :72 - 80.
4Earl SF,Wayne HG,William HD. Prevalence of the metabolic syndrome and among adults: finding from the third national health and nutrition examination survey[ J]. JAMA ,2002,287 (3) :356.
5Gu DF, Reynolds, Wu XG, et al. Prevalence of the metabolic syndrome and overweight among adults in China[ J]. Lancet,2005,365 (4968) :1398 - 1405.
6Grundy SM, Brewer B, Cleeman Jl, et al. Definition of metabolic syndrome report of the national Heart,Lung,and Blood Institute/American Heart Association conference on scientific issues related to definition[ J ]. Circulation ,2004,109 ( 3 ) :433 - 438.
9Recasens M, Lopez-Bermejo A, Ricart W, et al. An inflammation score is better associated with basal than stimulated surrogate indexes of insulin resistance [ J ]. J Clin Endocrinol Metab, 2005,90 (1):112-116.
10Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that Creactive protein becrease eNOS expression and bioactivity in human aortic endothelial cells [ J ]. Circulation, 2002,106 ( 12 ) : 1439 - 1441.
2Huber SA,Sakkinen P.Interleukin-6 exacerbates early atherosclerosis in mice ioscler. Thrombvasc Biol,1999,19(10):2364-2367.
3Fernandez JM,Ricart RM.Insulin resistance and inflammation in an evolutionaryperspective:thecontributionofcytokinegenotype/phenotype to thriftiness. Diabetologia, 1999,42:1367-1374.
4Fernandez-Reallemos JM.Insulin resistance and evolation. Hosp,2002,17(Suppl 1):60-66.
5Coppack SW.Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc, 2001,60(3):349-356.
6Marette A.Mediators of cytokine-induced insulin resistance in obesity and other inflammatory se ttings. Nutr Metab Care,2002,5(4):377-378.
7Bastard JP.Aplipose tissue IL-6 content correlates with resistance to insuin activation of glucose uptake both in vivo and in vitro. Clin Endocrinol Metab, 2002,87(5):2084-2089.
8Ross R.Atherosclerosis an inflammatory disease. New Engl J Med, 1999,340:115-126.
9Kaul D. Molecular link between cholesterol,ytokines andatherosclerosis.Mol Cell Biochem Zool Mau ,219(1-2):65-71.
10Kado S, Nagase T, Nagata N.Circulating levels of interleukin-6,its soluble receptor and interleukin-6/inteleukin-6 receptor complexes in patients with type 2 diabetes mellitus.Diabetol,1999,36(l-2):67-72.
3LARDIZABAL J A, DEEDWANIA P C. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus[J].Curr Cardiol Rep, 2010,12:464-471.
4YOUNIS F, STERN N, LIMOR R, et al. Telmisar- tan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via per~oxisome proliferator activator receptor-gamma activation[J]. Metabolism,2010,59 : 1200- 1209.
5SANCHEZ MUNOZ-TORRERO J F, RIVAS M D, COSTO A, et al. Telmisartan improves insulin resist- ance in patients with low cytokine levels[J]. J Inves- tig Med, 2011,59 : 602-605.
6THATCHER S, YIANNIKOURIS F, GUPTE M, et al. The adipose renin-angiotensin system., role in cardiovascu- lar disease[J].Mol Cell Endocrinol,2009,302 : 111- 117.
7WANG C, MAO X, WANG L, et al. Adiponectin sen- sitizes insulin signaling by reducing p70 S6 kinase-media- ted serine phosphorylation of IRS-1 [J]. J Biol Chem,2007,282:7991-7996.
8TIAN F, LUO R, ZHAO Z, et al. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes [J]. Exp Clin Endocrinol Diabetes, 2 010,118:2 5 8 - 2 6 5.
9Lardizabal JA, Deedwania PC. The role of re- nin- angiotension agents in altering the natu- ral history of type 2 diabetes melitus[ J]. Curt Cardiol Rep,2010,12(6) :464 -471.
10Thatcher S, Yiannkouris F, Gupte M,et al. The adipose renin - angiotensin system: Role in cardiovascular disease [ J ]. Mol Cell Endocri- nol,2009,302(2) :111 - 117.
